Featured
Pharma sold at undisclosed price
An international private equity firm has reached an agreement to acquire this pharma, with plans to support its global growth ambitions
Industry & Companies
Roche unveils new tech for high-throughput genomics
The Swiss pharma is gathering experts to push its entrant into the booming next-generation sequencing market
Industry & Companies
Was this Aussie pharma's Best Kept Secret?
A bombshell announcement from two industry high-flyers was kept completely under wraps despite multiple big-name organisations getting on board with the new pharma venture. And now, they've detailed a potentially market-disrupting business model for medicines access
Regulatory & Reimbursement
New drugs flood the ARTG
Last week saw a string of medicines registered on the ARTG, including two heart drugs, a new contraceptive option, and Novo’s hyped obesity pill
Latest
Matt Zeller launches new Australian pharma
Five months after leaving Arrotex, the former Novartis Country President ANZ is launching his own Sydney-headquartered pharma company with another high-profile exec as Co-Founder
Featured
Boosting PBS spending a political no-brainer
New research commissioned by Pfizer Australia exposes near-universal public support for expanding the PBS among Coalition, Labor, Greens and One Nation voters
Leadership & People
Pfizer names permanent ANZ leader
He knows plenty about the role, having served as interim Managing Director for six months, now this leader has officially landed the top job, providing certainty for the pharma as it navigates a changing reimbursement landscape
Industry & Companies
Pharma sells off Aussie business
This company will now be a specialty pharma focused on the United States with its Australian assets moving to new hands for $55M
Regulatory & Reimbursement
Drugs dropped from PBAC meeting
Three drugs were removed and another added in a last-minute revision to the agenda for the PBAC's last three-day meeting for 2026
Pipeline & Intellectual Property
Pharma signs its biggest ever milestones deal
Mega license agreement inked with Chinese powerhouse covering six antibody-drug conjugate and T-cell engager programs
Regulatory & Reimbursement
What drugs are on MS patients' Wish List?
While RRMS is a PBS success story with Australians having the best access to meds in the world, there are new drugs coming that also need to be funded
Patients
Omico names genomic profiling partners
Four organisations have been selected to provide comprehensive genomic profiling for 25,000 Australians in the next phase of this screening program
Featured
Country boss adds new leadership hat
AstraZeneca leader joins board to promote trade between Europe and Australia bolstering collaboration, innovation and investment
Featured
What doctors really want Reps to talk about
More than four in 10 clinicians say conversations with reps are mostly about products but what they'd really like to discuss is this...
Jobs
Regulatory & Reimbursement
11 drugs join TGA review list
An update to the TGA's prescription medicines under evaluation list shows 11 drug applications were accepted in August, signalling what could enter the Australian market next year
Pipeline & Intellectual Property
Drug fails four months after $2.2B upfront buy
Potential first-in-class treatment for a disease with high unmet need falls at the finish line of a pivotal trial after this pharma paid a hefty price in July
Industry & Companies
One webpage, 11 Code Breaches
The hardline UK industry watchdog is at it again, slapping a company with 11 breaches of the Code over a single webpage on a Congress website after a complaint from an ex-employee which described the company's missteps as an embarrassment to the industry
Government & Policy
Blue wave to break against MFN
The MFN isn't going anywhere soon, and the Commonwealth will need to adjust its pricing expectations if it wants Australians to gain access to the latest medicines
Pipeline & Intellectual Property
Can pharma sustain the blockbuster boom?
The number of blockbuster drugs have skyrocketed, with a new report taking a deep dive into whether industry can sustain the boom in the face of looming patent cliffs
Regulatory & Reimbursement
Aussie race to market kicks off for obesity pills
The first oral GLP-1 drug has been approved for use in Australia for weight loss and will likely hit the private market this year, with a rival hot on its heels
Industry & Companies
Who's opening its doors in the US?
Just months after undergoing a major rebrand, this Australian biotech is embarking on its next phase of growth, with plans to establish a US subsidiary
Regulatory & Reimbursement
Pharmac says no to weight loss funding
The decision came despite a high-priority recommendation from its Advisory Group with the current fiscal environment and constraints of the public health system to blame
Industry & Companies
AZ shuffles jobs to prep huge pipeline
The UK pharma giant has announced a "reshaping" programme which will see jobs lost in some areas but gained in others
Awards
Meet the Best Drugs of 2026
A drug currently seeking to unlock broader government subsidy in Australia was crowned one of the best products of 2026 at the Prix Galien USA awards
Regulatory & Reimbursement
Aussie study applauds new-gen Novartis drug
South Australian researchers have described one of Novartis' fastest-growing brands as "a huge step forward" in frontline treatment options
Featured
Aussies tapped for regional roles
In the latest round of job moves, industry leaders move up alongside long-timers changing companies - one after almost 30 years working at the same pharma
Leadership & People
Ex-Novartis GM snapped up for global role
So that's where he's gone... Well-known Aussie pharma exec has been tapped for a global position, joining a new company at a time of significant growth
Regulation & Legal
Federal Court slaps company with $6.5M fine
TGA wins its case against a company which unlawfully advertised prescription-only medicines, which the judge described as a "deliberate commercial strategy"
Pipeline & Intellectual Property
Qld radiopharma defends manufacturing process
AdvanCell has challenged two patent application by a Norwegian company that cover the production of the radioisotope used in its flagship product
Pipeline & Intellectual Property
Aussies find new combo to tackle deadly cancer
After this drug wowed ESMO last month Australian researchers have discovered another combo that could disrupt treatment for small cell lung cancer
- Government & Policy AbbVie pitches a world-class PBS
- Regulatory & Reimbursement Aussies continue FDA winning streak
- Regulatory & Reimbursement Three pharmas hit with first rival
- Regulatory & Reimbursement Who nabbed half the November PBS listings?
- Regulatory & Reimbursement Is the era of rising drug prices over?
- Government & Policy Guild turns up heat on PBS prices
- Industry & Companies Out-of-pocket obesity drugs drives Lilly profits
- Other News Health leaders of tomorrow start here
- Patients Patients pick favourite pharma
- Pipeline & Intellectual Property Six-way legal stoush over $47.5M market